FDA Panel Endorses New COVID-19 Vaccine Targeting JN.1 Lineage for Fall
A federal advisory panel has recommended that the new COVID-19 vaccine for fall should target the JN.1 lineage, which has been driving recent cases. The FDA is expected to use this recommendation to develop vaccines, with manufacturers like Pfizer, Moderna, and Novavax prepared to produce JN.1-targeted vaccines by August. This decision follows a decline in vaccination rates and aims to provide better protection against expected winter upticks in COVID-19 cases.